Medications such as NMDAR antagonists and acetylcholinesterase (AChE) inhibitors have been approved by the US FDA for the management of Alzheimer’s disease [37,38]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.